Martina Sundqvist

Martina Sundqvist

Auto-generated profile, based on publicly available information

Martina Sundqvist

Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
MMMarco Maugeri
Marco Maugeri
Nawaz MuhammadNawaz Muhammad
Nawaz Muhammad
APAlexandros Papadimitriou
Alexandros Papadimitriou
AAAnnelie Angerfors
Annelie Angerfors
ACAlessandro Camponeschi
Alessandro Camponeschi
Hadi ValadiHadi Valadi
Hadi Valadi
RNA-based therapeutics hold great promise for treating diseases and lipid nanoparticles (LNPs) represent the most advanced platform for RNA delivery. However, the fate of the LNP-mRNA after endosome-engulfing and escape from the autophagy-lysosomal pathway remains unclear. To investigate this, mRNA (encoding human erythropoietin) was delivered to cells using LNPs, which shows, for the first time, a link between LNP-mRNA endocytosis and its packaging into extracellular vesicles (endo-EVs: secreted after the endocytosis of LNP-mRNA). Endosomal escape of LNP-mRNA is dependent on the molar ratio between ionizable lipids and mRNA nucleotides. Our results show that fractions of ionizable lipids and mRNA (1:1 molar ratio of hEPO mRNA nucleotides:ionizable lipids) of endocytosed LNPs were detected in endo-EVs. Importantly, these EVs can protect the exogenous mRNA during in vivo delivery to produce human protein in mice, detected in plasma and organs. Compared to LNPs, endo-EVs cause lower expression of inflammatory cytokines.

1 December 2015 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
HBHalla Björnsdottir
Halla Björnsdottir
AWAmanda Welin
Amanda Welin
EMErik Michaëlsson
Erik Michaëlsson
VOVeronica Osla
Veronica Osla
SBStefan Berg
Stefan Berg
JBJohan Bylund
Johan Bylund

19 February 2023 in Advanced Science
Verified
Journal Article
Open access
Nawaz MuhammadNawaz Muhammad
Nawaz Muhammad
SHSepideh Heydarkhan‐Hagvall
Sepideh Heydarkhan‐Hagvall
BTBenyapa Tangruksa
Benyapa Tangruksa
HGHernán González‐King Garibotti
Hernán González‐King Garibotti
YJYujia Jing
Yujia Jing
Hadi ValadiHadi Valadi
Hadi Valadi
Lipid nanoparticles (LNPs) are currently used to transport functional mRNAs, such as COVID‐19 mRNA vaccines. The delivery of angiogenic molecules, such as therapeutic VEGF‐A mRNA, to ischemic tissues for producing new blood vessels is an emerging strategy for the treatment of cardiovascular diseases. Here, the authors deliver VEGF‐A mRNA via LNPs and study stoichiometric quantification of their uptake kinetics and how the transport of exogenous LNP‐mRNAs between cells is functionally extended by cells’ own vehicles called extracellular vesicles (EVs). The results show that cellular uptake of LNPs and their mRNA molecules occurs quickly, and that the translation of exogenously delivered mRNA begins immediately. Following the VEGF‐A mRNA delivery to cells via LNPs, a fraction of internalized VEGF‐A mRNA is secreted via EVs. The overexpressed VEGF‐A mRNA is detected in EVs secreted from three different cell types. Additionally, RNA‐Seq analysis reveals that as cells’ response to LNP‐VEGF‐A mRNA treatment, several overexpressed proangiogenic transcripts are packaged into EVs. EVs are further deployed to deliver VEGF‐A mRNA in vitro and in vivo. Upon equal amount of VEGF‐A mRNA delivery via three EV types or LNPs in vitro, EVs from cardiac progenitor cells are the most efficient in promoting angiogenesis per amount of VEGF‐A protein produced. Intravenous administration of luciferase mRNA shows that EVs could distribute translatable mRNA to different organs with the highest amounts of luciferase detected in the liver. Direct injections of VEGF‐A mRNA (via EVs or LNPs) into mice heart result in locally produced VEGF‐A protein without spillover to liver and circulation. In addition, EVs from cardiac progenitor cells cause minimal production of inflammatory cytokines in cardiac tissue compared with all other treatment types. Collectively, the data demonstrate that LNPs transform EVs as functional extensions to distribute therapeutic mRNA between cells, where EVs deliver this mRNA differently than LNPs.

17 January 2014
Verified
Book Chapter
Closed access
PDF file
JBJohan Bylund
Johan Bylund
HBHalla Björnsdottir
Halla Björnsdottir
MSMartina Sundqvist
Martina Sundqvist
AKAnna Karlsson
Anna Karlsson
CDClaes Dahlgren
Claes Dahlgren

6 September 2010 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
KBKelly L. Brown
Kelly L. Brown
PWPer Wekell
Per Wekell
VOVeronica Osla
Veronica Osla
MSMartina Sundqvist
Martina Sundqvist
KSKarin Sävman
Karin Sävman
SBStefan Berg
Stefan Berg
This study aimed to profile levels of blood cells and serum cytokines during afebrile and febrile phases of periodic fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA) syndrome to advance pathophysiological understanding of this pediatric disease.

1 May 2018 in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
Verified
Journal Article
Closed access
MSMartina Sundqvist
Martina Sundqvist
KCKarin Christenson
Karin Christenson
AHAndré Holdfeldt
André Holdfeldt
MGMichael Gabl
Michael Gabl
JMJonas Mårtensson
Jonas Mårtensson
HFHuamei Forsman
Huamei Forsman